Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests
13.12.2021 11:00:00 EET | Business Wire | Press release
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field and in-process testing applications requiring qualitative to semi-quantitative test results.
This portable instrument is a highly flexible, easy to use and accurate imaging platform used for lateral flow assay analysis. RapidScan ST5-W is unique to the market with its flexibility, multiple target analysis and its compatibility with applications for Eurofins Technologies’ allergen, GMO, glyphosate and algal toxins lateral flow tests. The reader performs well both in laboratories and in field testing environments, where quick results are needed for contamination analysis. With a data storage capacity of up to 5000 test results, reports are easy to create and export.
A wide range of Eurofins Technologies’ rapid test applications are already validated on the RapidScan reader, including gluten (allergen), corn, soybean and canola (GMO), glyphosate (pesticide) and algal toxins (toxins in drinking and fresh water) lateral flow assays. Further test validations will follow in 2022, including more than 20 allergens and additional GMO rapid testing capability.
This new reader will play an instrumental role in Eurofins Technologies’ mission to provide an integrated solution to its food and water safety customers. The reader provides a reliable and quick way to test for multiple contaminations with high-quality lateral flow devices and obtain and analyse results with a single reader platform at any environment and within just a few minutes.
About Eurofins Technologies
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative methods and applications. For further information, please visit the Eurofins Technologies website.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005046/en/
Contact information
For more information:
http://www.eurofins-technologies.com/
Dr. Gábor Kohut
Eurofins Technologies
GaborKohut@eurofins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 09:05:00 EET | Press release
EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to renewable energy, stable power grid, technical workforce and strong sustainability framework alig
Lyten Completes Acquisition of Northvolt Sweden and Establishes its First Lyten Industrial Hub in Sweden27.2.2026 09:00:00 EET | Press release
Lyten, a global leader in lithium-sulfur batteries and energy storage, announced today that it has completed the acquisition of Northvolt Ett and Ett Expansion (Skellefteå, Sweden) and Northvolt Labs (Västerås, Sweden). The Northvolt Sweden acquisition includes 16 GWh of existing battery manufacturing capacity, more than 160 hectares of land, infrastructure and buildings to support expanded manufacturing and industrial activities, and the largest and most advanced battery research and development center in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226538293/en/ Northvolt Labs, the largest battery research and development facility in Europe. Located in Västerås, Sweden. Lyten additionally announced the formation of the Lyten Industrial Hub, located in Skellefteå, at the Northvolt Ett site. The industrial hub will utilize the infrastructure built by Northvolt and access to abundant, clean hydro power to co-loca
SOLUM and Competera Expand Partnership to Integrate AI-Driven Pricing Solutions with Real-Time ESL Execution Across Europe27.2.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Competera announced the expansion of their strategic partnership to further connect AI-driven pricing intelligence with real-time Electronic Shelf Label (ESL) execution across European retail networks. The announcement follows strong engagement at EuroShop, where the integrated solution attracted significant interest from the local retail operators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226065052/en/ SOLUM and Competera announced the expansion of their strategic partnership (Image: SOLUM) The collaboration brings together Competera’s AI-driven pricing solutions for enterprise retail with SOLUM’s Newton ESL platform, enabling retailers to align advanced price optimization with synchronized shelf-edge communication. Competera’s platform applies machine learning and advanced analytics to help retailers balance competitiveness and value-based pricing, strengthen customer loyalty, improve pri
OpenSynergy's Blue SDK Now Drives More Than 400 Million Cars27.2.2026 09:00:00 EET | Press release
OpenSynergy's Blue SDK, the industry-leading independent Bluetooth® stack, is now deployed in over 400 million cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226654887/en/ OpenSynergy's Blue SDK now drives more than 400 million cars OpenSynergy is thrilled and very proud to announce that Blue SDK is now integrated in more than an estimated 400 million cars worldwide, deployed by virtually all the major OEMs across a wide range of vehicles, segments, and markets, offering extensive and consistent interoperability between many generations of smartphones and cars. “This is an incredible milestone for OpenSynergy, but it is also a testament to the ubiquity of the Bluetooth standard in our everyday lives and the success of the entire Bluetooth ecosystem under the leadership of the Bluetooth SIG,” comments Kathleen Ende, CEO, OpenSynergy. “Blue SDK is now an essential part of the daily automotivecockpit plug and play expe
Galderma’s Nemluvio ® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.1,6,7 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226796734/en/ “Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom